China 
Africa 
Explore chapters and articles related to this topic
Clinical Applications of Immunoassays
Published in Richard O’Kennedy, Caroline Murphy, Immunoassays, 2017
Systemic sclerosis is a multisystem connective tissue disorder and is characterised by thickening and fibrosis of the skin (scleroderma). There are two disease patterns comprising diffuse cutaneous systemic sclerosis (dcSS) and limited cutaneous systemic sclerosis (lcSS) based on the extent of skin involvement. In dcSS, sclerotic skin is seen on the trunk and proximal limbs as well as face and distal limbs and is associated with a worse prognosis. In lcSS, scleroderma is restricted to the face, neck and limbs distal to the elbow and knee and generally has a better prognosis when compared to dcSS. Many patients with lcSS have the CREST syndrome, which is an acronym for calcinosis, Raynaud’s disease, esophageal dysmotility, sclerodactyly and telangiectasia.
Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Published in Richard K. Burt, Alberto M. Marmont, Stem Cell Therapy for Autoimmune Disease, 2019
Andrew M. Yeager, Diane BuchBarker, Thomas A. Medsger, Albert D. Donnenberg
Systemic sclerosis is a chronic disorder of connective tissue characterized by inflammation and fibrosis of, and degenerative changes in, the blood vessels, skin, synovium, skeletal muscle, and certain internal organs, especially the gastrointestinal tract, lung, heart and kidney.1 Although there is an early and often clinically unappreciated inflammatory component, the hallmark of the disease is skin thickening (scleroderma) caused by excessive accumulation of connective tissue. Subintimal proliferative vascular changes are prominent and lead to Raynaud’s phenomenon and obliterative arteriolar and capillary lesions.
In vivo assessment of antioxidant, antigenotoxic, and antimutagenic effects of bark ethanolic extract from Spondias purpurea L
Published in Journal of Toxicology and Environmental Health, Part A, 2022
Lorrane Davi Brito, Caroline de Souza Araujo, Dalita Gomes Silva Moraes Cavalcante, Andressa Silva Gomes, Marcos Alberto Zocoler, Eidi Yoshihara, Aldo Eloizo Job, Leandra Ernst Kerche
DNA damage may be induced by mutagenic compounds used for the treatment of many diseases. Cyclophosphamide (CP) is a mutagenic drug used to treat cancer (Drimal et al. 2006) and nonmalignant diseases, such as systemic sclerosis, organ transplantation, autoimmune, and immune-related disorders (Ahlmann and Hempel 2016; McCurdy and Luznik 2019; Suga et al. 2020). DNA is affected by CP through its alkylating properties and as a consequence of oxidative stress (Song et al. 2014; Zhang et al. 2005). The oxidative environment is the main cause of the toxicity attributed to CP administration since this drug elevates the rates and number of superoxide radicals and hydrogen peroxide generated (Ettawa et al. 2016; Gunes et al. 2017; Iqubal et al. 2019).